Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Research and reports in urology

The diagnosis and management of prostate cancer involves the interpretation of data from multiple modalities to aid in decision making. Tools like PSA levels, MRI guided biopsies, genomic biomarkers, and Gleason grading are used to diagnose, risk stratify, and then monitor patients during respective follow-ups. Nevertheless, diagnosis tracking and subsequent risk stratification often lend itself to significant subjectivity. Artificial intelligence (AI) can allow clinicians to recognize difficult relationships and manage enormous data sets, which is a task that is both extraordinarily difficult and time consuming for humans. By using AI algorithms and reducing the level of subjectivity, it is possible to use fewer resources while improving the overall efficiency and accuracy in prostate cancer diagnosis and management. Thus, this systematic review focuses on analyzing advancements in AI-based artificial neural networks (ANN) and their current role in prostate cancer diagnosis and management.

Van Booven Derek J, Kuchakulla Manish, Pai Raghav, Frech Fabio S, Ramasahayam Reshna, Reddy Pritika, Parmar Madhumita, Ramasamy Ranjith, Arora Himanshu

2021

active surveillance, artificial intelligence, clinical trials, prostate cancer